Health - Google News: Acorda's Ampyra fails main goal of post-marketing study - Reuters

Health - Google News Google News

Acorda's Ampyra fails main goal of post-marketing study - Reuters Aug 13th 2012, 11:40 eYugoslavia.com Acorda's Ampyra fails main goal of post-marketing study Reuters (Reuters) - Acorda Therapeutics Inc said a post-marketing study of its multiple sclerosis drug Ampyra failed to meet the main trial goal of an improvement in patients' walking speed. The 5 mg and 10 mg doses of Ampyra did not yield statistically ... Acorda Therapeutics: Study Shows 5-Milligram Dose of Ampyra Not EffectiveWall Street Journal Acorda Reports Top Line Results of Study Exploring 5 mg Dose of Dalfampridine-ERRTT News Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment ...Benzinga all 16 news articles »

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

Posted in: